LHRH-analogues therapy for metastatic prostate cancer
Debruyne, F.M.; Fernandez del Moral, P.; Geboers, A.D.
Progress in Clinical and Biological Research 260: 27-39
1988
ISSN/ISBN: 0361-7742 PMID: 2966406 Document Number: 323720
Document emailed within 1 workday
Related Documents
Keizman, D.; Eisenberger, M.A. 2009: LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy? Oncology 23(7): 631-632Abbou, C.C.; Lucas, C.; Leblanc, V. 1997: Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(6): 984-995
Labrie, F.; Dupont, A.; Giguère, M.; Borsanyi, J.P.; Lacourciere, Y.; Bélanger, A.; Lachance, R.; Emond, J.; Monfette, G. 1988: Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer Progress in Clinical and Biological Research 260: 41-62
Leewansangtong, S.; Soontrapa, S. 2003: The pattern of prostate-specific antigen responses following hormonal therapy in Thai men with bone metastatic prostate cancer Journal of the Medical Association of Thailand 86(9): 809-815
Olsson, J.O. 1990: Orchiectomy or LHRH analogues in prostatic cancer? Lakartidningen 87(4): 190
Dondi, D.; Limonta, P.; Moretti, R.M.; Marelli, M.M.; Garattini, E.; Motta, M. 1994: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop Cancer Research 54(15): 4091-4095
Reddy, S.V.; Gupta, S.K. 2012: Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singapore Medical Journal 53(3): E52-E54
Wilking, N.; Rutqvist, L.E. 1990: LHRH analogs versus orchidectomy in prostate cancer Lakartidningen 87(16): 1344-1345
Crawford, E.D.; Hou, A.H. 2009: The role of LHRH antagonists in the treatment of prostate cancer Oncology 23(7): 626-630
Wenderoth, U.K.; Jacobi, G.H. 1986: Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin Annales d'Urologie 20(2): 95-97
Behrakis, P.; Koutsilieris, M. 1997: Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy Anticancer Research 17(3a): 1517-1518
Bessoule, O.; Le Loët, X.; Deshayes, P. 1988: Importance of analogs of LHRH in the treatment of bone metastasis of cancer of the prostate in 1988 Revue du Rhumatisme et des Maladies Osteo-Articulaires 55(11): 885-887
Debruyne, F.M.; Karthaus, H.F.; Schröder, F.H.; de Voogt, H.J.; de Jong, F.H.; Klijn, J.G. 1985: Results of a Dutch Phase Ii trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer Progress in Clinical and Biological Research 185a: 251-270
Schmeller, N. 1992: A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy? Der Internist 33(4): 284
Sandow, J. 1983: Clinical applications of LHRH and its analogues Clinical Endocrinology 18(6): 571-592
Anderson, K.E. 1989: LHRH analogues for hormonal manipulation in acute intermittent porphyria Seminars in Hematology 26(1): 10-15
Incorvaia, L.; Badalamenti, G.; Rini, G.; Arcara, C.; Fricano, S.; Sferrazza, C.; Di Trapani, D.; Gebbia, N.; Leto, G. 2007: MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone Anticancer Research 27(3b): 1519-1525
Celebi, M.M.; Venable, D.D.; Nopajaroonsri, C.; Eastham, J.A. 1997: Prostate cancer metastatic only to the penis Southern Medical Journal 90(9): 959-961
Amsellem, D.; Ogiez, N.; Salomon, L.; Chopin, D.; Abbou, C.C.; Colombel, M. 1998: Does PSA of less than 20 ng/ml exclude the diagnosis of metastatic prostate cancer? Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 8(6): 1018-1021
Cicin-Sain, D.; Pasini, J. 1989: New possibilities in the hormonal therapy of metastatic carcinoma of the prostate Lijecnicki Vjesnik 111(11): 405-407